| Schedule of investment in associates |
Schedule
of investment in associates
| | |
2026 | | |
2025 |
|
| | |
USD | | |
USD |
|
| | |
| | |
|
|
| Unquoted shares - at cost | |
| | | |
| |
|
| As at April 1 | |
| 1,493,850 | | |
| 1,493,850 |
|
| Unquoted shares - at cost beginning | |
| 1,493,850 | | |
| 1,493,850 |
|
| Disposal during the financial year | |
| (677 | ) | |
| - |
|
| Reclassification to Other Investment during the financial year (Note 8) | |
| (1,492,955 | ) | |
| - |
|
| | |
| | | |
| |
|
| As at March 31 | |
| 218 | | |
| 1,493,850 |
|
| Unquoted shares- at cost end | |
| 218 | | |
| 1,493,850 |
|
| | |
| | | |
| |
|
| Less: Accumulated impairment loss | |
| | | |
| |
|
| As at April 1 | |
| (257 | ) | |
| (257 |
) |
| Accumulated impairment loss beginning | |
| (257 | ) | |
| (257 |
) |
| Reversal of impairment during the financial year | |
| 263 | | |
| - |
|
| Exchange difference | |
| (6 | ) | |
| - |
|
| | |
| | | |
| |
|
| As at March 31 | |
| - | | |
| (257 |
) |
| Accumulated impairment
loss ending | |
| - | | |
| (257 |
) |
| | |
| | | |
| |
|
| Unquoted shares- at cost,
net | |
| 218 | | |
| 1,493,593 |
|
| | |
| | | |
| |
|
| Share of post-acquisition reserve | |
| | | |
| |
|
| As at April 1 | |
| 3,151 | | |
| 13,911 |
|
| Share of post-acquisition reserve beginning | |
| 3,151 | | |
| 13,911 |
|
| Share profit((loss) during the financial year | |
| 14,449 | | |
| (10,760 |
) |
| | |
| | | |
| |
|
| As at March 31 | |
| 17,600 | | |
| 3,151 |
|
| Share of post-acquisition reserve ending | |
| 17,600 | | |
| 3,151 |
|
| | |
| | | |
| |
|
| Share of post- acquisition reserve, net | |
| 17,818 | | |
| 1,496,744 |
|
| Exchange differences | |
| 788 | | |
| 99,432 |
|
| | |
| | | |
| |
|
| Investment in associates | |
| 18,606 | | |
| 1,596,176 |
|
|
| Schedule of details of associates |
The
details of associates are as follows:
Schedule
of details of associates
| | |
Place of business/ Country of | |
Effective equity |
|
|
|
| Name of Company | |
incorporation | |
interest |
|
|
Principal activities |
| | |
| |
2026 | | |
2025 | |
|
|
| | |
| |
% | | |
% | |
|
|
| Vax Biotech Sdn. Bhd. (“Vax Biotech”) | |
Malaysia | |
| - | | |
| 30 | % |
|
Manufacture of medicaments |
| | |
| |
| | | |
| | |
|
|
| Alps Globemedics Sdn. Bhd. (“Alps Globemedics”) | |
Malaysia | |
| 30 | % | |
| 30 | % |
|
Marketing of health and beauty product and services |
| | |
| |
| | | |
| | |
|
|
| Cilo Cybin Holdings Limited (“Cilo Cybin”) | |
South Africa | |
| - | | |
| 40.5 | % |
|
Investment in biotech, biohacking and pharmaceutical businesses |
|
| Schedule of financial information represents the amount in the financial statements |
Schedule
of financial information represents the amount in the financial statements
| Alps Globemedic Sdn Bhd | |
2026 | | |
2025 | |
| | |
USD | | |
USD | |
| | |
| | |
| |
| Statement of financial position | |
| | | |
| | |
| Non-current assets | |
| 3,274 | | |
| 3,529 | |
| Current assets | |
| 190,038 | | |
| 36,502 | |
| | |
| | | |
| | |
| Total assets | |
| 193,312 | | |
| 40,031 | |
| | |
| | | |
| | |
| Current liabilities | |
| (131,329 | ) | |
| (16,483 | ) |
| | |
| | | |
| | |
| Total liabilities | |
| (131,329 | ) | |
| (16,483 | ) |
| | |
| | | |
| | |
| Net assets of the associate | |
| 61,983 | | |
| 23,548 | |
| | |
| | | |
| | |
| Statement of comprehensive income | |
| | | |
| | |
| Revenue for the financial year | |
| 268,615 | | |
| 187,465 | |
| | |
| | | |
| | |
| Profit for the financial year | |
| 34,606 | | |
| 7,375 | |
| | |
| | | |
| | |
| Share of profit of the associate | |
| 10,382 | | |
| 2,213 | |
|